Patent application number | Description | Published |
20090275126 | ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF - Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy. | 11-05-2009 |
20110059093 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 03-10-2011 |
20110143372 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue. | 06-16-2011 |
20110165592 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue. | 07-07-2011 |
20120122120 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor. | 05-17-2012 |
20120269723 | COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT - The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-25-2012 |
20120282280 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES - This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof. | 11-08-2012 |
20120321633 | ANTI-HUMAN EPO RECEPTOR ANTIBODIES AND METHODS OF USE - Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD. | 12-20-2012 |
20130078251 | ANTI-MCSP ANTIBODIES - The invention provides anti-MCSP antibodies and methods of using the same. | 03-28-2013 |
20130310541 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 11-21-2013 |
20140193418 | ANTI-HUMAN EPO RECEPTOR ANTIBODIES AND METHODS OF USE - Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD. | 07-10-2014 |